Product class: Authorized package
Medicinal product class: For human use
Package code: 1373060
Name of medicinal product: DOXORUBICIN ACCORD 2 MG/ML
Active substances:
Estonian, English, Latin
ATC code: L01DB01
Dosage form: concentrate for solution for infusion
Route of administration: intravenous use
Strengh: 2mg 1ml
Amount in package: 5ml 1TK
Legal status for supply*: Subject to medicinal prescription
Class of active substance:  
Additional information:  
Indication: Doxorubicin is indicated in the following neoplastic conditions, Examples include: - Small-cell lung cancer (SCLC) - Breast cancer - Advanced ovarian carcinoma - Intravesically for bladder cancer - Neoadjuvant and adjuvant therapy of osteosarcoma - Advanced soft-tissue sarcoma in adults - Ewing's sarcoma - Hodgkin's disease - Non-Hodgkin's lymphoma - Acute lymphatic leukaemia - Acute myeloblastic leukaemia - Advanced multiple myeloma - Advanced or recurrent endometrial carcinoma - Wilms' tumour - Advanced papillary/follicular thyroid cancer - Anaplastic thyroid cancer - Advanced neuroblastoma Doxorubicin is frequently used in combination chemotherapy regimens with other cytotoxic drugs.
Safety features: Yes
Summary of product characteristics (SPC):  (last updated 15 February 2024)
Package information leaflet (PIL): EST  (last updated 15 February 2024)
Labelling:  (last updated 20 March 2019)
Last imported to Estonia: 21 May 2021
Marketing authorization holder: Accord Healthcare B.V. 
Marketing authorization number: 690810 
Marketing authorization issued on: 29 June 2010 
Marketing authorization expires on: Unlimited 
Marketing authorization procedure type: Decentralised 
Reference price:   
Under reference price:   
Reference price of daily dose:   
Entry/Changing date: 15 February 2024
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription